Skip to main content
Clinical Trials/NCT05127460
NCT05127460
Completed
Not Applicable

Computer-assisted Atrial Fibrillation Risk Detection In Oral-anticoagulant Use, Lowering Stroke Risk, and Optimizing Guidance With an Intelligent Screening Tool (CARDIOLOGIST): a Pragmatic Randomized Controlled Trial

National Defense Medical Center, Taiwan1 site in 1 country25,732 target enrollmentJanuary 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation New Onset
Sponsor
National Defense Medical Center, Taiwan
Enrollment
25732
Locations
1
Primary Endpoint
Proportion of taking AF treatment medications
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of Atrial Fibrillation.

Registry
clinicaltrials.gov
Start Date
January 1, 2022
End Date
January 31, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
National Defense Medical Center, Taiwan
Responsible Party
Principal Investigator
Principal Investigator

Chin Lin

Assistant Professor

National Defense Medical Center, Taiwan

Eligibility Criteria

Inclusion Criteria

  • Patients in emergency department or inpatient department
  • Patients had at least 1 ECG
  • Patients cared by non-cardiologist

Exclusion Criteria

  • Patients without history of atrial fibrillation diagnosis.
  • Patients without history of long-term NOAC or warfarin usage.
  • Patients without history of hemorrhagic stoke or ishemic stroke.
  • Patients with low eGFR (\<30 ml/min)

Outcomes

Primary Outcomes

Proportion of taking AF treatment medications

Time Frame: Within 90 days

defined as use of long-term NOAC (apixaban, rivaroxaban, endoxaban, dabigatran).

Proportion of ischemic Stroke

Time Frame: Within 90 days

After performing an electrocardiogram, the patient's physical conditions is tracked.

Secondary Outcomes

  • Proportion of hemorrhagic stroke(Within 90 days)
  • Proportion of all cause mortality(death)(Within 90 days)
  • Proportion of cardiologist consultation(Within 90 days)
  • Proportion of new-onset heart failure(Within 90 days)
  • Proportion of new-onset AF diagnosis(Within 90 days)
  • Proportion of echocardiogram performed after ECGs(Within 90 days)
  • Proportion of gastrointestinal bleeding(Within 90 days)

Study Sites (1)

Loading locations...

Similar Trials